| 000 | 01751 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515104212.0 | ||
| 264 | 0 | _c20080519 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a0091-2700 | ||
| 024 | 7 |
_a10.1177/0091270007311111 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Yaning | |
| 245 | 0 | 0 |
_aLeveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cFeb 2008 |
||
| 300 |
_a146-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aClinical Trials as Topic _xmethods |
| 650 | 0 | 4 | _aDecision Making |
| 650 | 0 | 4 |
_aDrug Approval _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aDrug Industry _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aGovernment Regulation |
| 650 | 0 | 4 | _aGuidelines as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInvestigational New Drug Application _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aLegislation, Drug _xstandards |
| 650 | 0 | 4 | _aOrganizational Objectives |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 700 | 1 | _aBhattaram, A Venkatesh | |
| 700 | 1 | _aJadhav, Pravin R | |
| 700 | 1 | _aLesko, Lawrence J | |
| 700 | 1 | _aMadabushi, Rajanikanth | |
| 700 | 1 | _aPowell, J Robert | |
| 700 | 1 | _aQiu, Wei | |
| 700 | 1 | _aSun, He | |
| 700 | 1 | _aYim, Dong S | |
| 700 | 1 | _aZheng, Jenny J | |
| 700 | 1 | _aGobburu, Jogarao V S | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 48 _gno. 2 _gp. 146-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0091270007311111 _zAvailable from publisher's website |
| 999 |
_c17707989 _d17707989 |
||